CSI Market
Sign In | Register

Ani Pharmaceuticals Inc (ANIP) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ANIP quarterly Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Ani Pharmaceuticals Inc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income78.34
Depreciation & amortization91.42
Amortization of Other Assets1.36
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.77
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-5.96
Research and Development in Process0.00
Gain (Loss) on Disposition of Other Assets0.38
Share-based Compensation37.93
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Excess Consideration Paid Over Fair Value-
Increase Decrease In Accrued Compensation Liabilities-
Increase Decrease Accrued Government Rebates24.44
Operating Lease Right Of Use Asset Amortization Expense1.76
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability Cash Flow-31.01
Increase Decrease In Royalty Payable-
Income taxes14.24
Losses/ -gains on Investments net0.00
Accounts Receivable-74.06
Increase (Decrease) in Accounts Payable15.16
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense-5.02
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities35.50
Discontinued operations0.00
Net Cash flow from Operating Activities185.23
Investing Activities
Capital Expenditures-34.32
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Indefinitelived Intangible Assets Acquired-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-34.32
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-10.16
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.40
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-144.92
Proceeds From Issuance Of Common Stock By Underwritten Public Offering-
Payments To Fractional Share Payout-
Payments For Fractional Share Payout-
Repayments Of Short Term Convertible Debt-
Payment For Treasury Stock Purchases For Restricted Stock Vestings And Forfeitures-
Cash And Cash Equivalents And Restricted Cash And Cash Equivalents Current And Noncurrent-
Restricted Cash And Cash Equivalents Noncurrent-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents144.89
Payments Of Debt Issuance Costs And Convertible Debt Repurchase Costs-
Proceeds From Lines Of Credit Long Term-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid-1.16
Net Cash Flow from Financing Activities-9.94
Effect of exchange rate on cash flow-0.23
Discontinued operations0.00
Free Cash Flow150.90
Total Cash Flow140.73
4 historic quarters locked

Sign in to unlock the full Ani Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Ani Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 27, 2026
  • Source: anip-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001023024-26-000014

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License